Showing 4391-4400 of 7033 results for "".
- FDA Warns Public About Black Henna Tattoo Riskshttps://practicaldermatology.com/news/fda-warns-public-about-black-henna-tattoo-risks/2458159/Black henna temporary tattoos can cause serious skin reactions, the US Food and Drug Administration (FDA) warns. For centuries, traditional henna, a reddish-brown plant extract, has been used to dye skin, hair, and fingernails in parts of Asia and Northern Africa. Henna is
- Murad Adds Two New Blemish-busting Products for Acne Awareness Monthhttps://practicaldermatology.com/news/murad-adds-two-new-products-for-acne-awareness-month/2458161/June is acne awareness month, and Murad is rolling out two anti-acne new products to help patients say goodbye to blemishes. The new Pore Extractor Pomegranate Mask ($38 from Murad.com) features volcanic clay, pomegranate extract and lactic aci
- HED Research Fuels Understanding of Male Pattern Baldnesshttps://practicaldermatology.com/news/hed-research-fuels-understanding-of-male-pattern-baldness/2458162/The origins of hypohidrotic ectodermal dysplasia (HED) may help researchers get a better handle on the genetic underpinnings of common hair disorders. The findings appear in Nature Communications. About one in 5,000 to 10,000 people are thought to have HED, although this
- Game Change: New Handheld Tissue Scanner Can See Below Surface of Skin in Psoriasishttps://practicaldermatology.com/news/game-change-new-handheld-tissue-scanner-looks-below-surface-of-skin-in-psoriasis/2458166/A new handheld tissue scanner allows dermatologists to look below the surface of skin in psoriasis patients and can provide clinically relevant information, such as the structure of skin layers and blood vessels, without the need for contrast agents or radiation exposure. A team of r
- Sun Pharma Announces US FDA Filing Acceptance of Biologics License Application For Tildrakizumabhttps://practicaldermatology.com/news/sun-pharma-announces-us-fda-filing-acceptance-of-biologics-license-application-for-tildrakizumab/2458175/The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Sun Pharma’s tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis. The
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte
- Fibrocell to Continue Phase 1/2 Clinical Trial of FCX-007 for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-to-continue-phase-12-clinical-trial-of-fcx-007-for-recessive-dystrophic-epidermolysis-bullosa/2458193/Fibrocell Science, Inc.’s Data Safety Monitoring Board (DSMB) has recommended continuation of the Phase 1/2 clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), following a review of safety data from the first patient treated. No product-re
- BioPharmX Reports Positive Topline Results of BPX-01 Topical Minocycline for Acnehttps://practicaldermatology.com/news/biopharmx-reports-positive-topline-results-of-bpx-01-topical-minocycline-for-acne/2458198/BioPharmX Corporation’s topical minocycline for acne, BPX-01, achieved its primary endpoint in a phase 2b clinical trial. There were statistically significant reductions in non-nodular inflammatory acne lesions when compared to vehicle in both the 1 percent and 2 percent doses of BP
- Abeona Therapeutics Provides Update on EB-101 Gene Therapy for Severe Form of Epidermolysis Bullosahttps://practicaldermatology.com/news/abeona-therapeutics-provides-update-on-eb-101-gene-therapy-for-severe-form-of-epidermolysis-bullosa/2458202/Abeona Therapeutics, Inc. has announced updated clinical data from the ongoing Phase 1/2 clinical trial for the EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB), a severe fo
- Forging Ahead For Clear-Cut Best Practices for MOHS Surgeryhttps://practicaldermatology.com/news/forging-ahead-for-clear-cut-best-practices-for-mohs-surgery/2458204/New research on the average number of surgical slices made during Mohs micrographic surgery (MMS) will serve as a first step towards identifying best practices for MMS, as well as identifying and informing physicians who may need re-training because their practice patterns deviate far from their